Click on headlines below to download research

Termination of coverage
Termination of coverage - ReNeuron Group | 22/03/2024

Edison Investment Research is terminating coverage on ReNeuron Group (RENE). Please note you should no longer rely on any previous research or estimates…

H124 results reaffirm focus on CustomEX
ReNeuron Group | 27/11/2023

ReNeuron has announced its H124 results (to end-September 2023), reaffirming its commitment to advance CustomEX(TM), its proprietary stem cell-derived…

A step forward on the Exosome delivery platform
ReNeuron Group | 15/09/2023

ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While…